---
title: "Entyvio (vedolizumab), all indications: Specific populations questions"
description: "Specific populations questions on Entyvio (vedolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Can Entyvio be used during pregnancy? Can Entyvio be used while breastfeeding? Can children use Entyvio? Is Entyvio safe and effective for adults 65 and older? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/entyvio/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab), all indications: Specific populations questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)  
Indication pages: [Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)

## Pregnancy and breastfeeding

<a id="entyvio-pregnancy"></a>

### Can Entyvio be used during pregnancy?

> “Available data from the Organization of Teratology Information Specialists (OTIS)/
> MotherToBaby ENTYVIO Pregnancy Registry, published literature and pharmacovigilance 
> in pregnant women have not reliably identified an ENTYVIO-associated risk of major birth 
> defects, miscarriage or adverse maternal or fetal outcomes (see Data). There are risks 
> to the mother and the fetus associated with inflammatory bowel disease in pregnancy
> (see Clinical Considerations).”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

> “ENTYVIO administered during pregnancy could affect immune responses in the in utero-
> exposed newborn and infant. The clinical significance of low levels of ENTYVIO in utero-
> exposed infants is unknown.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

> “The proportion of major birth defects among live-born infants in patients with UC or CD 
> treated with vedolizumab and patients with UC or CD treated with other biological products 
> was 7.4% (7/94) and 5.6% (4/71), respectively. Overall, there was no evidence of increased 
> risk for major structural birth defects (adjusted RR 1.07, 95% CI: 0.33, 3.52).
> The methodological limitations of the registry, including small sample size and the non-
> randomized design, resulted in a limited ability to estimate the risk of major birth defects 
> and other maternal and infant outcomes.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

<a id="entyvio-breastfeeding"></a>

### Can Entyvio be used while breastfeeding?

> “Data from a clinical lactation study show the presence of vedolizumab in human milk. 
> The mean calculated daily infant dosage was 0.02 mg/kg/day orally (see Data). Systemic 
> exposure in a breastfed infant is expected to be low because monoclonal antibodies are 
> largely degraded in the gastrointestinal tract. There are no data on the effects of vedolizumab 
> on the breastfed infant, or the effects on milk production. The developmental and health 
> benefits of breastfeeding should be considered along with the mother’s clinical need for 
> ENTYVIO and any potential adverse effects on the breastfed infant from ENTYVIO or from 
> the underlying maternal condition.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

## Pediatric use

<a id="entyvio-children"></a>

### Can children use Entyvio?

> “Safety and effectiveness of ENTYVIO in pediatric patients have not been established.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

## Specific populations

<a id="entyvio-older-adults"></a>

### Is Entyvio safe and effective for adults 65 and older?

> “Clinical trials of ENTYVIO did not include sufficient numbers of patients aged 65 and over 
> (72 patients with Crohn’s disease or ulcerative colitis aged 65 and over were treated with 
> ENTYVIO during controlled Phase 3 trials) to determine whether they respond differently 
> from younger adult patients. However, no overall differences in safety or effectiveness were 
> observed between these patients and younger adult patients, and other reported clinical 
> experience has not identified differences in responses between the elderly and younger 
> patients.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

<a id="entyvio-kidney-liver-impairment"></a>

### Has Entyvio been studied in kidney or liver impairment?

> “Pharmacokinetics of vedolizumab in patients with renal or hepatic insufficiency have not 
> been studied.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “Population pharmacokinetic analysis showed that the severity of disease state, body 
> weight, prior treatment with TNF blocker therapy, age (18 to 78 years), serum albumin, 
> coadministered immunomodulators (including azathioprine, 6-mercaptopurine, 
> methotrexate), and coadministered aminosalicylates did not have a clinically meaningful 
> effect on the pharmacokinetics of ENTYVIO.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

## Related pages
- [Medical information: Entyvio (vedolizumab): All indications](https://www.evicenter.com/medical-information/entyvio)
- [Indication](https://www.evicenter.com/medical-information/entyvio/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/entyvio/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/entyvio/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio/access-and-coverage)
